Updated analysis from a phase 2 study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable/metastatic microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) solid tumors.

被引：0
|
作者：
Li, Jian
Xu, Ye
Zang, Aimin
Gao, Yunong
Gao, Quanli
Zhang, Yanqiao
Wang, Dong
Xu, Jianming
Yuan, Ying
Jiang, Haiping
Ying, Jieer
Shi, Chunmei
Deng, Yanhong
Wang, Jing
Liu, Tianshu
Huang, Yi
Xu, Yaling
Wang, Yidi
Fei, Cong
Shen, Lin
机构：
[1] Beijing Canc Hosp, Beijing, Peoples R China
[2] Fudan Univ Shanghai, Canc Ctr, Shanghai, Peoples R China
[3] Hebei Univ, Affiliated Hosp, Hebei, Peoples R China
[4] Henan Canc Hosp, Zhengzhou, Henan, Peoples R China
[5] Harbin Med Univ, Canc Hosp, Harbin, Peoples R China
[6] Chongqing Univ, Canc Hosp, Chongqing, Peoples R China
[7] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 5, Beijing, Peoples R China
[8] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Zhejiang, Peoples R China
[9] Med Sch Zhejiang Univ, Affiliated Hosp 1, Zhejiang, Peoples R China
[10] Zhejiang Canc Hosp, Beijing, Peoples R China
[11] Fujian Med Univ, Union Hop, Fujian, Peoples R China
[12] Sun Yat Sen Univ, Affiliated Hosp 6, Guangzhou, Peoples R China
[13] Hunan Canc Hosp, Changsha, Hunan, Peoples R China
[14] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China
[15] Hubei Canc Hosp, Wuhan, Hubei, Peoples R China
[16] BeiGene Co Ltd, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14556
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Updated analysis from a phase 2 study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable/metastatic microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) solid tumors
    Li, Jian
    Xu, Ye
    Zang, Aimin
    Gao, Yunong
    Gao, Quanli
    Zhang, Yanqiao
    Wang, Dong
    Xu, Jianming
    Yuan, Ying
    Jiang, Haiping
    Ying, Jieer
    Shi, Chunmei
    Deng, Yanhong
    Wang, Jing
    Liu, Tianshu
    Huang, Yi
    Xu, Yaling
    Wang, Yidi
    Fei, Cong
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [2] Long-term follow-up of a phase II study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors
    Li, J.
    Xu, Y.
    Zang, A.
    Gao, Y.
    Gao, Q.
    Zhang, Y.
    Wang, D.
    Xu, J.
    Yuan, Y.
    Jiang, H.
    Ying, J.
    Shi, C.
    Deng, Y.
    Wang, J.
    Liu, T.
    Huang, Y.
    Shi, M.
    Wang, K.
    Hu, H.
    Shen, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S640 - S640
  • [3] Tislelizumab in previously treated, locally advanced unresectable/metastatic microsatellite instability-high/ mismatch repair-deficient solid tumors
    Li, Jian
    Xu, Ye
    Zang, Aimin
    Gao, Yunong
    Gao, Quanli
    Zhang, Yanqiao
    Wang, Dong
    Xu, Jianming
    Yuan, Ying
    Jiang, Haiping
    Ying, Jieer
    Shi, Chunmei
    Deng, Yanhong
    Wang, Jing
    Liu, Tianshu
    Huang, Yi
    Qian, Xiaoping
    Pan, Yueyin
    Cheng, Ying
    Hu, Sheng
    Wang, Jin
    Shi, Mengyue
    Wang, Ke
    Hu, Han
    Shen, Lin
    CHINESE JOURNAL OF CANCER RESEARCH, 2024, 36 (03)
  • [4] Tislelizumab in previously treated, locally advanced unresectable/metastatic microsatellite instability-high/mismatch repair-deficient solid tumors
    Jian Li
    Ye Xu
    Aimin Zang
    Yunong Gao
    Quanli Gao
    Yanqiao Zhang
    Dong Wang
    Jianming Xu
    Ying Yuan
    Haiping Jiang
    Jieer Ying
    Chunmei Shi
    Yanhong Deng
    Jing Wang
    Tianshu Liu
    Yi Huang
    Xiaoping Qian
    Yueyin Pan
    Ying Cheng
    Sheng Hu
    Jin Wang
    Mengyue Shi
    Ke Wang
    Han Hu
    Lin Shen
    ChineseJournalofCancerResearch, 2024, 36 (03) : 257 - 276
  • [5] A phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced unresectable ormetastatic microsatellite instability-high/mismatch repair deficient solid tumors.
    Li, Jian
    Xu, Ye
    Zang, Aimin
    Gao, Yunong
    Gao, Quanli
    Zhang, Yanqiao
    Wang, Dong
    Xu, Jianming
    Yuan, Ying
    Jiang, Haiping
    Ying, Jieer
    Shi, Chunmei
    Deng, Yanhong
    Wang, Jing
    Liu, Tianshu
    Huang, Yi
    Li, Zhezhen
    Wang, Huanli
    Liu, Shou
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] Phase 2 study of tislelizumab monotherapy in previously treated, locally advanced, unresectable or metastatic microsatellite instability-high/mismatch repair-deficient solid tumors: Gynecological cancer subgroup
    Wang, Dong
    Zhang, Naiyi
    Zang, Aimin
    Wang, Jing
    Huang, Yi
    Shen, Lin
    Li, Jian
    Zhang, Yanqiao
    Liu, Tianshu
    Deng, Yanhong
    Xu, Yaling
    Li, Zhezhen
    Wang, Yidi
    Gao, Yunong
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S80 - S81
  • [7] Iparomlimab (QL1604) in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic solid tumors: a pivotal, single-arm, multicenter, phase II trial
    Bi, Feng
    Dong, Jian
    Jin, Chuan
    Niu, Zuoxing
    Yang, Wenhui
    He, Yifu
    Yu, Dajun
    Sun, Meili
    Wang, Teng
    Yin, Xianli
    Zhang, Ruixing
    Chen, Kehe
    Wang, Keming
    Wang, Zhiwu
    Li, Wei
    Zhang, Zhongtao
    Zhang, Hangyu
    Guo, Qunyi
    Wang, Xin
    Han, Lei
    Zhang, Xizhi
    Shen, Wei
    Zhang, Liangming
    Ying, Jieer
    Wu, Miao
    Hu, Weiguo
    Li, Zeng
    Li, Xiaofen
    Feng, Wenlei
    Zhang, Baihui
    Li, Lingyan
    Kang, Xiaoyan
    Guo, Weijian
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2024, 17 (01)
  • [8] Pembrolizumab in microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) advanced solid tumors: An update of the phase II KEYNOTE-158 trial
    Maio, M.
    Ascierto, P. A.
    Motola Kuba, D.
    Penel, N.
    Cassier, P. A.
    Bariani, G. M.
    De Jesus-Acosta, A.
    Doi, T.
    Longo Munoz, F.
    Miller, W. H.
    Oh, D-Y.
    Gottfried, M.
    Yao, L.
    Jin, F. J.
    Gozman, A.
    Marabelle, A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S589 - S590
  • [9] A single-arm, phase II, multicenter study of iparomlimab (QL1604) in patients (pts) with unresectable/metastatic deficient mismatch repair (dMMR)/microsatellite instability high (MSI-H) solid tumors
    Guo, W.
    Bi, F.
    Dong, J.
    Jin, C.
    Niu, Z.
    Wang, Y.
    Sun, M.
    Wang, T.
    Yu, D.
    He, Y.
    Zhang, R.
    Yin, X.
    Feng, W.
    Zhang, M.
    Li, L.
    Zhang, B.
    Kang, X.
    ANNALS OF ONCOLOGY, 2023, 34 : S1511 - S1511
  • [10] Clinicopathological and genomic characteristics of DNA Mismatch Repair-Deficient (dMMR) and microsatellite instability-high (MSI-H) resected gastric adenocarcinoma
    Zhou, J.
    Liang, B.
    Yin, M.
    Zhang, H.
    Liu, F.
    Dong, L.
    Zhang, B.
    Xu, Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S921 - S922
12345